Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution  by Bourke, John P. et al.
IMX “0, 16. NO. 7 
DcEEmkr 19HI:l7o*Io 
1703 




JOHN P. BOURKE, MB, MRCPI. AI Ah A. YOUNG, FRACP. FRCP, 
DAVID A. B. RICHARDS, MD, FRACP. FACC. JOHN B. UTHER, MD. FRACP 
Westmeod, New S”“lh Wales, /l,,srm,in 
-- 
The aim of tbtsshldy wps todetermine whether intrwenous 
streptokiame administered with or without omt aspirin 
to patients with evolving mywmdial infarcttoo r&w 
the btducibtlity of venttiular tacbycsrdtt at etectrophyrt. 
a&c study and thus the tik of sudden death in infarct 
suNtvor8. or 159 patients random~ed at Westme& nor. 
dtal B the multicenter Second fntemational Studv of 
and sspirln zi patients; both placebos 21 patimlsi. Patients 
who mdmmt electmphysidogic testing bad similar 
cUtcat dwxterisib to thwz of patents who did not. The 
stint- pmtoml comprised op to and imludttg four 
ubutlmuli np&d to the ttgbt venlricntar apex *t khe 
di&dic thresh&% An abnormal result was definer’ as 
_ 
Thrambolytic agents administered during the cvoki wry 
phase of acute myocardii infarction significantlv reoxe 
mortality and preserve ventricular function (l-5). Eowever, 
even after successful thrombolysis. the infarct zone :msistr 
of varying pmporlioss of necrotic to viable myocxdium. 
depending on the delay to reperfusion (6.7). The exaggerated 
anatomic heterogeneity in the infarct zone resulting Tmm 
thrombolysis is likely to persist through the various stages of 
infarct maturation and there remains the oossibilitv that it 
migh! increase the likelihood of subsequeot w&at wa- 
tricular fachyxrbythmias. This possibility that thrombolytic 
ventricdar tachyeardia with n qcle length aZ30 ms Ming 
at0 s, 
Ventricular bwhyrardta WLT inductble at ohtrcp$s& 
lotic study ia a ~ntienls who received &c&o ~tretioki- 
n&e, but in no p&nt rho received z&e streptc&w (8 
of 46 venw 0 of 0,; p = O.WS, Ft.&r’s cxpc, test,. 
Ventricular lacbycardis was inducible in 4 p&cots who 
received qdrin tbrrapy 8nd 4 who did m4 (4 ef 41 versus 
4 ot 46; p = NS,. During s mepn fottowup porkxd of 39 * 
9 lnontbs, tbhere were “rJ spontanews episodes of “co,rkn- 
tar Lachycardis, rentr*ulrrtibriltsttwcrHlmcmd sudden 
death in the streptokinax.tRsted gnmp ccmpued with 
three such events in the placebc-treated gmup (p = 0.13). 
When mmpwed with ptxebo therapy, intrwMous 
dreptokbmse subrtanttty reduced *be incidence of indue 
ibte ventricular caebyrardht tntr&mt mwivcm. No nbnilnr 
bmetit was attribntalde to arpb-bl therapy. 
(J Am Cd Cadid 1990;16:170340) 
agents might paradoxically increase the arrhythmogenic 
legacy of myccardial infarction in humans while still reduc- 
ing c?wall in’arct-related mortality remains a concern that 
has not been adequately studied to date (8-10). 
The aims ~Fthis study were I) to compare the incidence 
of inducible ventricular tachycardia in patients treated with 
streptokinase versus placebo, and 2) to determine whether 
the incidence of witnessed sudden death and sp+ntanew 
ventricular tachycardia and fibrillation during a prolonged 
follow-up period was influenced by streptokinase therapy. 
Methods 
Study patient% In the period from August 1985 to Ihem- 
ber 1987. patients were enrolled at Westmead Hospital into 
the randomized multiccater p:asebo.controlled Second In- 
tematioxal Study of Infarct Survival (ISIS-2) (1) after treat- 
ment with weptokinase with or without aspirin in cornpar- 
ison with pfacebo in acute myocardial infarction. During the 
samt: period, programmed electrical siimulation was being 
&red at the time of hospiral discharge to all patients 
surviving acute myocardial infarction as part of a separate 
study (I tl to evaluate the risk of spontaneous ventricular 
tachyarrhythmias and sudden death in infarct survivors. The 
present study reports the ekctrcphysiolagic results and 
subsequent follow-up data for all Westmead Hospital pa- 
tients entered into ISIS-2. All study protocols were ap 
proved by the Research and Ethics Committees at West- 
mead Hospital, and all patients gave informed written 
consent to participate in each part of the study. 
Entrv criteria md mndokzatian into ISIS-2 studv. En- 
rollment criteria and results of ISIS-2 have been rep&d in 
detail (Il. Patients <70 veals of see were entered into the 
study lfihey were thought to be within 24 h of the onset of 
symptoms of suspected myocardial infarction and to have no 
contraindication to streptokinase or aspirin therapy. Patients 
were randomized to active or placebo streplokinase and 
active or placebo aspirin by means of a 24 h telephone 
servi-e based at Oxford, England, if certain baseline require- 
ments were met. The compoter used a minimization algo- 
rithm to reduce the chance of differences occurring between 
the treatment groups in proguostic features recorded at entry 
(12). To gain entry to !SIS-2 at this hospital, all patien!s were 
requirtd tn have 22 mm ST swnent elevation on their 
admission electrocardiogram (EC&. 
Streptokhxw protocol. The study design randomized 
50% of the patients to receive streptokinare (1.5 million U) 
and 50% to receive matching placebo (hepatitis-R antigen- 
free albumin) infused intravenously over about I h in 50 to 
WJ ml of normal saline solution. Half of all patients were 
also randomized to receive oral aspirin (162.5 mg i 1 cnteric- 
coated tablets) or matching placebo daily, starting immedi- 
ately and continued for I month. This resulted m four 
separate artns to ISIS-2. allowing distinction between the 
beneficial effects of streptokinase and those of aspirin. 
Selection criteria and proload for eloebophyslologlc teit- 
ing. Patients C71 years of age in whom the diagnosis of 
myocxdial infarction could be confirmed by standard syma- 
tom, ECG eld enzyme criteria were offered invasive ele~s 
trophysiologtc testing between days 6 and 28 after infarction 
to determine their risk of arrhylhmias during the follow-up 
period. Predetermined exclusion criteria for electroohvsio- 
logic testing included ongoing ischemia requiring thekpy, 
uncontrolled heart failure despite treatment and owurrenw 
of spontaneour ventricular tachycardia >48 h after the onset 
of acute infarction. Patients were also excluded il they or 
their cardiologists refused consent for the test. 
Elecrrophysiologic testing was performed wtth patients in 
the postabsorptive state under diazepam sedation and 1% 
lignocaine local anesthesia. Programmed electrical stimula- 
tion was performed at twice diastolic threshold at the right 
ventricular apex using a World Precision Instruments pro- 
grammable stimulator, applying; rectangular 2 ms pulse stim- 
uli. Extrastimuli were applied zifteran e&ht beat drive train 
at a cycle length of 600 ms. A 3 s pause was inserted before 
the next drive train. The ir.itial coupling interval was set at 
3Cdl ms and then decreased in IO ms steps ro ventricular 
refractoriness. Each extrastimulus coupling interval was 
delivered three times before the next IO ms shorter interval 
was intmduced. If the earliest possible extrastimulus failed 
to induce ventricular tachycardia, that extrastimulus was 
placed IO ms outside the ventricular eiiective refractory 
~&cd and an additional extrastimulus added. The additional 
extrastimulus was used to scan diastolc in the same manner. 
Additional extrastimuli were added until ventricular tachy- 
cardia, flutter or fibrillation was induced or refractoriness of 
the fourth extrastimulus was reuched. Induced arrhythmirs 
were terminated either by overdrive pacing or by diict 
current cat’diowsion. On the basis of previous work at this 
unit (1 I) in patients after myocardial infarction, only ventric- 
ular tachycardia with a cycle length a230 ms lasting >I0 s 
was taken as an abnormal result. No patient was given 
prophylactic antiarrhythmic drug therap& on the b&is of 
results of postinfarction electrophysioloaic testing. 
Aw&nIs during initial a&i&on. -On entr)Fto ISIS-2, 
age, gender, duration of ischemic symptoms. history of prior 
infarction and location of current infarction were remrded. 
In addition, peak rreatine kinase level, radioisotopic I& 
ventricular ejection fraction and 24 h ambulatory ECG were 
later recorded whenever possible. The results of amtulatory 
ECG recordings were not used to select patients for electro- 
physiologic study and, in most patients, the recordings had 
not been performed before consent for the electrophysio- 
logic test was requested. 
Follow-up. Fo!law-up dam were obtained by telephone 
contact with patients, their immediate relatives, their medi- 
cal attendants or B combination of these at 3 month intervals. 
For the purpose of this study, only documented spontaneous 
vetttricular tachycardia. ventricular fibrillation and wit- 
nested sudden death in the absence of symptoms of ischemia 
were considered end points predicted by elenrophysiologic 
tesdna. When a oatient had died. the relatives and ncneml 
practitioner were interviewed to determine the cause of 
death. All oatients enrolled in ISIS-2 were followed uo for 
>I year &er ‘Leir index infarction. In the subgro;p of 
patients who had undergone electrophysiologle testing, fob 
low-up study was extended to December I, 1989 to allow 
maximal opportunity for spontaneous arrhytbmic events to 
occur. 
Use of beta.adrencrglc hlaxking and other anti,urhjib:nlc 
drugs. Neither beta-adrenergic blocking agents nor orher 
auiiarrhythmic drugs were prescribed routinely to patients 
with or without inducible ventricular tachvcardia or Wzh 
grade ventricular ectoPh activity. Patients who erperienad 
spontaneous sustained ventricular tachycardia during t!.e 
follow-up period were withdrawn from the study and anti r- 
rhythmic dreg therapy was directed by the results of renal 
electrophysialogic studies. Whcr patients were withdrawn 
from follow-up evalaation if :hey died from any cause or 
suffered reinfarction. 
Statistical analysis. Compatisons bc:aeeo groups were 
made using unpaired Student’s t fat and cht-square analysi, 
where appropriate. Fisher‘s exact test and Ya!:s‘ correc!ed 
c&square nnalysis were usrd for compansons of 9rn311 
numberr 
Results 
Randomized group charaeterirtics. In the period from 
August ,985 to December ,987. 159 paoents from Westmead 
Hospital were entered into the mutticcoter. randomued. 
placebo-controlled ISIS-2 trial. Their mean age was 55 f IO 
years: 136 were male and 23 were female. On admission. 19 
were randomized to streptokinase treatment and 80 to pia- 
eebo treatment. Separate randomization resulted in 79 pa- 
tients receiving aspirin therapy and 80 receiving placebo 
aspirin. Random&ion resulihd in the active ani &cebo 
groups having comparable baseline clinical variables (Table 
I). Nine (6%) of the total group had either vemricular 
fibrillation. runs of ventricular &hvcardia or xc&rated 
jtmetional .rhythmr within 48 h of.symptom onset (two 
receivitw streatokinase and a&in. two receivine streotoki- 
nase, I& &iving aspirin anh three receiving both &ace- 
has). The index infarction was Q wave by ECG criteria in 47 
(60%) of thos& who received streprokinnse therapy com- 
oared with SO (63%) of those who did not (o = 0.69). 
The sttbgro& of 87 patients (20 w&vi& streptokinase. 
25 receiving aspirin. 21 receiving streptokinase and aspirin 
and 21 receiving both placebos) who underwent ekctrophys- 
ioloaic testina were also comoarabie in terms of baseline 
vari~blcs (Table 2) and i-cprc&tativc of the total group5 
from which they originated. lo those who underwent elec- 
trophysialagic testing, the index infarction was Q wave in 32 
(78%) of those who received streotokinase theraov coin- 
&d with 35 (76%) of those wh6 did not (p = -0. A 
similar number of patients who underwent electropbysio- 
logic SNdy from the active versus placebo streptokinase 
groups received their treatment within 3 h (19 verw 16; p > 
0.2) and within 6 h (27 versus 32; p = 0.71) of the onset of 
symptoms. Ambulatory ECG monitoring was performed in 
only 42 (26%) of the IS9 patiants (Table I), but the results 
(Tables I to 3) were not available before the patient’s 
consent for eleclrophysiologic study was requested. 
Reasons for failure to undergo cleelrophysiologit study. 
Seventy-two pattents (45% of the total gruup) did not UP- 
tlergo prognmmcd ehe,rical stimulafion within I month of 
their index infarction. Thirty-eight of these were from the 
streptokinase-treated group and 34 fmm the placebo-treated 
group (p = NS). Failure to undergo electrophysioloEic study 
was altcibuted to patient or physictan refusal iu 47 patients 
(29%) 126 in the streplokinase-treated group, 21 in the 
placebo-treated group), death or reinfarction before the day 
6 afXr infarction in 6 (4%) (1 in rhe stxptokinasc-treated 
group. 5 in tnc placebo-trcatcd group) and uncontrolled heart 
failure or ischemia despite therapy in 19 (12%) (II in the 
streptokinase-treated group. 8 in the placebo-treated group). 
El&l of proviotts Irq,loktMse therapy on Wdenec of 
inducil~lc vcnlrieulu taehyeardia after infruetioa. Eiitty 
seven paiients 155% of the !otal group) underwont pro- 
grammed electrical stimulation between days 6 and 28 after 
acute infarction. hfonomoQhic ventricular tachycardia with 
a cycl,. !cngth a230 ms and lasting 810 s was inducible in 
eight patirnts who were treated with piacebo on admission 
and in none who received streptokinase. This difference is 
highly significant, even allowing for the small patient num- 
bers (p = 0.005, Fisher’s exact test; p = 0.0125, chi-square 
analysis with Yates’ correction). Ventricular tachycardia 
was induced by the second extrastimulus in one patient. bg 
,hc ,hird in live and by the fourth in two. 
Spontaneous wntrie lar tachycardia or tiorillatiaI or wit- 
rie.wd sudden death dwiog fdlow-up. In the total ISIS-2 
patient cohort (n = 159) during a mean foilowup period of 
30 + I3 months, one pattznt was witnessed to die suddenly 
without prior ischema aad IWO survived spontanaous epi- 
sodes of ventricular wrhythr:ia. All three had received 
placebo streptokinase therapy at the time of their xute 
infarction. One additi.mal patient in the placebo-treated 
group died !wnitnesse.: and it was not possible to clarify 
whether the cause of death was related to new ischemiaor to 
a primary anhythmia. Thus, no patient who receiveti strep- 
lokinase at the time of the acute infarctimt hnd spontaneous 
ventricular arhythmic rvents as defined during the pro- 
ion&d follow-up period (p = 0.13). 
Table 2 summarizes the clinical events during mean 
follow-ur, r&d of 39 ? 9 months in the subemuo of 87 
I . 
patients&o underwent programmed electrical stimulation. 
Thirty-two (37%) of these patients were taking a heta- 
adrenergic blocking agent during the follow-up period (10 in 
the str:plo)linase-treated group, 22 in the placeboaeated 
group; p < 0.05). 
The three palien:; who cxperirnced the anhythmic 
events already referred to were from znong the 46 placebo 
strrptokinase-treated patients who unde,went electmphyri. 
ologic testing (3 of 46 wsus 0 of 41; p = L 14). One patient, 
a 68 year old !ttnan, was witnessed to die wldenly without 
Tsbk 3. Summay Details on the Subgroup of 87 Patients 





preceding ischemic symptoms 3 manlhs after his index 
infarction and 6 weeks after cormwry artay bypass gmtiiog. 
The second padent was a 70 year old man who had a 
Spontaneous episode of ventricular tachycardia 8 days after 
his index infarction. The arrhvtbia was monomo&ic with 
a cycle length of 320 ms and-occurred in the c~nt&t &left 
ventricular failure. This Went died of multiorean failure 69 
days after his infarction; following coronary &ety bypass 
grafting. Surgery had been performed to controi ischemic 
symptoms in the setting of three vessel coronary artery 
disease. The third patient, a 55 year old man, had an 
wymptoma:ic episcde of self-terminati,lg sustained ventric- 
ular tachycardia with a cycle length of 3:O ms precipitated by 
8~ exercise stress test. This occurred without demonstrable 
irchemia 4 months after his index idrction and 2 months 
after coronary artery bypass surgery. The arrhythmia re- 
~nained noninducible during a compreheosive repeat electm- 
physiologic test. This patient remain?J alive and free of 
lunhcr arrhythmias 31 months after infarction. Postinfarc- 
tion electmphysiologic testing would nm have been ex- 
pected to predict this airhythnne. 
That all three of the spontaneocis ventricular arthythmic 
events seen during the follow-up petiod occurred in patients 
:reated with placebo and that none occurred in those receiv- 
iy streptokinase suggest a clinical benefit of active treat- 
ment. However, lhis difference doe? not reach statlsticill 
significance because of the small number of patients and the 
low incidence of ventticular arrhythmias m the stcdy. 
Effect of aspirin therapy on inducible and spontsn~lur 
vehlricular Iachycardia atler myocardial infarction. There 
was no signilicwd difference in the inadence of inducible 
ve~tticular lachycardia at electrophysiologic testi- be 
tween patients ranJomized to receive ilclive in = 46) YEIW~ 
placebo (n = 41) aspirin therapy on admnsron. Dunng the 
fOlluW-up period, Iwo parienis from rhs xctivo asp&n- 
treated grow and on< from the placebo aspirin-treated group 
experienced spontaneous ventricular tachvarrhythmia$ (p = 
0.4). Table 3 summarizes the clinical characteristics and 
outcome of patients according to the!r randomization to 
active or placebo aspirin :berapy. 
Prediction of ~pontaneoos ~cntric~l~~ taebycardia during 
follmv-up by ek@mphysiolc@e study. Netthe, of the two 
oatients who manifested soontaneoos ventricular tachvcar- 
hia nor the one who u& witnessed to die sodden;; had 
inducible ventricular tashvcardia. as ore~~iouslv dehned. at 
the time of their eleciro~bysiolo~ ‘r?~dy. ?tte first had 
~ettlricolar fibrillation induced during the patinfdrction 
study, the second had ventricular flurter with a cycle length 
of IgO ms and the third had ventricular flutter with a cvck 
length of 200 to 210 ms. 
Of the eioht aatients who had inducible ventricular tachv- 
cardia with a c&e length 2230 SF.. seven are alive and none 
has experienced spontaneous a,~ hythmic episodes during a 
median follow-up period of 24 months (range I2 to 25). The 
eighth patient exeerienoed no ~oontaneous ventricular or- 
rb$hm& but d&d of metes& adenocarcinoms of the 
lung 7.7 months after his index infarction. Only one of these 
eight patients was taking bets:tdrcncrgic blocking mLdica- 
tion during the follow-up peri@ .tnd none was taking other 
antiarrhythmic medication. 
DiSCUS6!Oll 
The major finding of this placebo-controlled study is that 
streplokinane t!terapy in patients with evolving myccardial 
infarction sigttiftcantly reduced the subsequent incidence 01 
inducible vewricular tachycardia at eiectrophysiologic 
study. Furthermore. no such benefit was attributable to 
aspirin therapy. 
Previous studii on tke role of thmmbolytic tkerapy. Twa 
previous studies (13.14) compared the inducibility of vemric- 
ular tacbytwrbythmias by programmed stimulation in pa- 
tients who did or did not receive thrombolytic therapy at the 
time of their acute infarction. Kerssch?t et al. (13) studied a 
group of 36 patients and obsened a signifant rcductton in 
the incidence of indociole sustoine~ :entrioular tachycardii 
after infarction in patients treated on admission with a 
regimen of intravenous and iotracoronary streptokinnse plus 
aspirin compared with plecebc streptokinase and aspirin 
16 ot 21 xisus IO of IS; p c 0.05). Our larger mndomized 
xrles showed a highly signiiicant reduction in arrhythmia 
risk otter mfarction with an intravenous streptokinase re& 
men. The\e results demonstrate that the benefit dues no: 
depend on the rtreptokinase beiog admmistered by the 
intracoronary rou:: aoJ does not depend on concomitant 
asp,“” rhcrapy. 
In the second s13dy, Sager et al. (14) pelformed clcctro- 
phyxdogx stud&s in 20 patients who developed ,t left 
ventricular nxurysm after a Q waw anterior myomdial 
mfarctian. T\fe!ve had received thrombolytic therap, at the 
lime of awn infarction and eight had not. Patients uith an 
aneurysm iveie cnosen for electrophysiologic siody because 
they were cwnidered to be at particbiariy high risk <If 
experiencing rpontaneous ventricular tachyarrhythmiasdur- 
mg the follow-up period Ventricular tachycardia *as in&c- 
ible m seven patients (88%) who did not receive tbrom- 
bolytic therapy and in only one @%bl #ho did (p = O.ooO8). 
During a mean follow-up period of I I ? 8 months. no patieut 
who received thrombolytic therapy, compared with foor 
who did not have such therapy. experienced either spontu- 
neou~ arrhythmias or died suddenly. This nonrandomized 
srudy of highly selected survivors ofinfarction demonstrates 
that even in the absence of significant myocxdial salvage, 
thromboly+s reduces both inducible and spontaneous ven- 
tncular arrhythmias during the followup period. 
Gang et al. (IS) recently reponed a significant reduction 
in the tietection of ECG signal-avenged late potentials at the 
time of hospna, discharge 15% “ersus 23%; p = 0.01) m 
patienta who received tissue plasminogen activator ti.n- 
pared with placebo on admissioc. Their fir! J&s may a&o 
indirectly corroborate the results of our oresent study. 
CXcal impiications. The main impli&ion of this study 
is that patients who recetve streotokinsse would be expected 
to have a lower incidence of spbntaneoos vcntriculor~achy- 
cardia. ventricular fibrillation and witnessed sudden death 
during the follow-up period compared with those who do 
not. Revmus work at this unit (I I) in survivors of infarcZion 
who did not receive thrombcdytac therapy has shown thet 
about 25% of ptieets with inducible ventricular tachycardia 
as defined in this study will experience either spontaneous 
ventricular tachyarrhythmias or die suddenly within 2 years 
of :nfa;ctioo. ‘-‘he mean 30 month follow-up period m this 
p~eserit study. therefore. ailowed ample time for patients at 
risk to experience spattaneous ventricular arrhythmias. 
Patiats in the placebo-treated grcilp did indeed ht.vt a 
higher incidence of spontaneous ?irhylhmia events during 
the follow-up period both in the total ISIS-2 cohort (0 of 79 
on streptokmase versus 3 of 80 on placebo: p = ~1.13) and in 
the s&group of patients who und&went pr&ammed elcc- 
trical stimulation 10 of 41 on streptokinase versus 3 of 16 on 
ptwxbo: p = 0.14). The m&itude of these Cifferrnces 
suggests that the reduction in spontaneous atrhythmic 
wents during the follow-up period would have reached 
statistical sigmdcance if a larger patient cohort had been 
studied. 
To unequivocally establish that the lower inducibility of 
ventricular tachycardia after myocardial infarction in pa- 
tients who receive streptokinasc therapy translates into a 
significantly lower spontaneous arrhythmia event rate during 
the follow-un veriod would reauire a large scale randomized 
placebo-conir~lled trial. However, given the weight of evi- 
dence ahead, :stablishiq the benefits of thrombolytic ther- 
apy on overal .wrvival in patients with evolving myocardial 
infarction (I-5). it is unlikely that further placebo-controlled 
trials of this kind can be ju&ed. 
Mechanism of reduction af in&wible vmlricular taebycw 
din by sIreptokinnse. There are severnl mechanisms by 
which successful thrombolysis might reduce the arrhyth- 
mogenic legacy of myoardial infarction. Several studies 
(16-18) have shown that the iucidence of both inducible and 
spontaneous ventricular tnchycardia after myocardial iwfarc- 
tion increases as infarct size increases. By reducing infarct 
size alone, streptokinase may have prevented the formation 
ofthe critical mass of scar required for reentrant arrhythmias 
to occur in those patients in the strcptokinase arm of this 
study. The active &d placebo streptokinase-treated groups, 
however, had a similar mean ejection fraction after infarc- 
tion, which suggests that reduction in infarct size itself was 
not the sole mechanism of the reduction in arrhythmia 
toducibility in this series. 
The stntucw~ of the three-dimensional “border WIIE” 
between infarct edge and nortnal myocardium that results 
from infarct healing is a critical determinant of whether 
reentrant arrhythmias crut occur as a consequence of infarc- 
tion (18-21). It is in the brrder zones of the infarct showing 
neninsulas of survivine myocytes interdieitating with fibrous 
&sue (22) that inhom~ge~eo~s electric &&ion and slow 
conduction can be identified (IS-20). There electroahvsio- 
logic abnormalities are the hr&ttarks for identifying &ens 
capable of supporting reentrznt arrhythmias. If reperfusion 
modified the infarct-healing process, the formation of some 
sah arias might be prevented. 
Im,oorrani .ii&rences hove been idcnfifrd in fhe nature 
offhe cellular b&ate during healing of on infarct where 
reperfusion has and has not occurred (23). Differences have 
also been observed in the amount of hemorrhage (7,231. the 
proportion ofcollagen per unit area (23,24). its cmss-linkage 
and the properties of the resulting ihfarct scar (24). These 
differences are explained by the fact that repafusion washes 
out d.emotonins and other chemical mediators of infiamma- 
tion and collagen formation and facilitates a faster, more 
comprehensive removal of necrotic debris front the infarct 
zone (25). Keperfusion allows rapid fibroblast proliferation 
from multiple foci in the infarct zone, facilitated by the 
prcserwtioo of some ofthe reticulin, fibroblast and capillary 
framework. As a result, a crude restoration of the preinferct 
acbitecture of !he myocardium is possible (25). Oxygen- 
derived free radicals produced as a resuit of reperfusion (26) 
it: the infarct zone might destroy some adjacent peninsulas OF 
myocytes that would otherwise have survived the infarction. 
resulting in some smoothing of the infarct edges and wduc- 
ing the potential for reentrant arrhythmias. 
Limitnttons. A major theoretic limitation of this study is 
that ahhough the randomization prasess for ISIS-2 treatment 
(streptokin&e and aspirin) o&red after infortned consent 
had been obtained on admission, consent for the electro- 
physiologrc slvdy was sought significantly later in the hor- 
pital stay. The result was that only 55% of all randomized 
patients actually underwent electrophysiologic assessment. 
However, because both patients and physicians were 
blinded to the treatment randomization process thmughout 
the management period, it is unlikely that significant bias 
was introduced into the study by the exclusion of the 47 
randomized patients (2%) who refused electrophysiologic 
study. In fait, the number of pntients from the active and 
placebo slreptokinasetreated groups who refired consent 
wns comparable (26 receiving streptokinase, 21 receiving 
nlacebo: I) = NSI. The 25 randomized patients (16%) ex- 
&tded f&n electr~physiologic study be&se of early death, 
reinfarction or uncontrolled heart failure or ischemia could 
have biased the otitcowe of the study. Any bias introduced 
by the removal ofthese “high dsk” patients, however, could 
only have reinforced the benefits already demonstrated for 
streptokinase therapy because all early reinfarctmits oc- 
curred in the placebo-treated group (n = 4) and the nrlmbers 
excluded on other grounds were comparable (II receiving 
streptokinare, 8 receiving placebo; p = NS). 
’ second limirorion of the study is that electrophysiologk 
study failed to predict any of the three spontaneaus urrbyth- 
mia events that occurred duhg the follow-up period. How- 
ever, ventricular tachycardia occurred in one of the& pa- 
tients after exercise and was not subsequently inducible at 
repent electrophysiologic study. In another, a monomorphic 
venUicular anhythmia wns inducible at the postinfarction 
study but had a cycle length of 210 ms, 20 ms outside the 
arbitrary cut-off definitior. of an abnormal electrophysiologic 
test result. 
h addition, none of the eighr patienlv idenrifiea by 
programmed elecrrical srimulabn as being (11 risk experi- 
enced arrhythmias during the prAmged fidlow-up period. 
Stzlistically. two would have been :xpect,:d either to die 
suddenly or to have spontaneous ventricular tachycardia 
,xithin 2 years of infarction. Treattnent with beta-adrenergic 
blacking or other antiarrhythmic drugs did not explain the 
lack of spontaneous arrhythmias in these pdttents because 
only one of Ihe eight at risk was iaking such drugs during the 
follow-up period. Ii is possiblr that unidentified aspects of 
the rnana~ernent of these iafarct surviwrs &to altered their 
rate of sf&ttaneohs ! e?tricular arrhythmias. In fax, in the 
group as a whole. the we of a beta-adrener@c blocidng drug 
in more of tie placeba acptokinase-treated group may have 
masked an even grea!cr difference in the incidence of spon- 
taneous arrhythmic evenu during the follow-up period. The 
poor predictive accuracy of programmed electric stimulation 
for electric events in this study probably merely reflectc !he 
small samDIe size (27). Pre:ious lareer srudies (1 t.Z@-321 in 
conventionally treated infarct survivors using similsr proto- 
cols for electnphysiologic testing have clearly demonstrated 
the value of rlectrophyniologic testing in identifymg pat~ntr 
at high arrhythmic risk. recognizing both false negative and 
false positive results. 
Conclusions. The initial concerns that thrombolytlc Iher- 
spy might increaSe the risk of reentrant v;“tric”l”r mchy 
cardia and fibrillation after myocardral infarction wre rea- 
sonable and appeared justified (X-10). They were bawd, 
however. nn nonrandomized studies of very small numbers 
of patients and included a wide range of abnormal electr@ 
physiologic end points. This randomized placeboamtrolled 
study demonstrates that such concerns are no longer justi- 
fied..Effcctive tbrombolysis with streptokinase therapy slg- 
niticantly reduces the risk of reentmnt ventricular tachyar- 
rhythm& and sudden death after myoardial infarction by 
preventing the development of the substrate of ventricular 
electrical instability. 
These results provide yet another reason for asking 
thrombolytic treatment more readdy available to patients 
with evolving infarction. Prevenring the developmem of rhe 
arrhythmogenic milieu during acute myocardinl infarction by 
pmmp: thrombolysis is clearly a better rtlategy than at- 
tempts to con!rol ventricular tacbyarrhythmias once they 
ClCC”r. 
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